Kendrew J - Search Results

1

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.

McKillop D, Guy SP, Spence MP, Kendrew J, Kemp JV, Bushby N, Wood PG, Barnett S, Hutchison M. McKillop D, et al. Among authors: kendrew j. Xenobiotica. 2006 Jan;36(1):29-39. doi: 10.1080/00498250500523253. Xenobiotica. 2006. PMID: 16507511

2

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC. McKillop D, et al. Among authors: kendrew j. Mol Cancer Ther. 2005 Apr;4(4):641-9. doi: 10.1158/1535-7163.MCT-04-0329. Mol Cancer Ther. 2005. PMID: 15827338

3

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. Wedge SR, et al. Among authors: kendrew j. Cancer Res. 2005 May 15;65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409. Cancer Res. 2005. PMID: 15899831

4

Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Kettle JG, Kendrew J, Klinowska T, Ogilvie DJ, Pearson SE, Williams EJ, Wilson I. Ballard P, et al. Among authors: kendrew j. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4908-12. doi: 10.1016/j.bmcl.2006.06.054. Epub 2006 Jun 27. Bioorg Med Chem Lett. 2006. PMID: 16806916

5

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jürgensmeier JM, Wedge SR, Barry ST. Smith NR, et al. Among authors: kendrew j. Mol Cancer Ther. 2007 Aug;6(8):2198-208. doi: 10.1158/1535-7163.MCT-07-0142. Mol Cancer Ther. 2007. PMID: 17699717

6

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.

Kendrew J, Odedra R, Logié A, Taylor PJ, Pearsall S, Ogilvie DJ, Wedge SR, Jürgensmeier JM. Kendrew J, et al. Cancer Chemother Pharmacol. 2013 Apr;71(4):1021-32. doi: 10.1007/s00280-013-2097-x. Epub 2013 Jan 26. Cancer Chemother Pharmacol. 2013. PMID: 23355042

7

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. Wedge SR, et al. Among authors: kendrew j. Cancer Res. 2000 Feb 15;60(4):970-5. Cancer Res. 2000. PMID: 10706112

8

Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.

Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Curwen JO, et al. Among authors: kendrew j. Clin Cancer Res. 2008 May 15;14(10):3124-31. doi: 10.1158/1078-0432.CCR-07-4783. Clin Cancer Res. 2008. PMID: 18483380

9

Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.

Checkley D, Tessier JJ, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC. Checkley D, et al. Among authors: kendrew j. Magn Reson Imaging. 2003 Jun;21(5):475-82. doi: 10.1016/s0730-725x(02)00644-6. Magn Reson Imaging. 2003. PMID: 12878256

10

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.

Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Checkley D, et al. Among authors: kendrew j. Br J Cancer. 2003 Nov 17;89(10):1889-95. doi: 10.1038/sj.bjc.6601386. Br J Cancer. 2003. PMID: 14612898 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters